REG - Hemogenyx Pharma Plc - Institutional Fundraise

Hemogenyx PharmaceuticalsAnnouncement

28/04/2026 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260428:nRSb1094Ca&default-theme=true

RNS Number : 1094C  Hemogenyx Pharmaceuticals PLC  28 April 2026

 28 April 2026

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK
VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH
LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED.  ON
PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS
INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Hemogenyx Pharmaceuticals plc

("Hemogenyx Pharmaceuticals" or the "Company")

Hemogenyx Secures £3,000,000 to accelerate its Phase 1 Clinical Trials and
initiate early commercialization of HG-CT-1

 

Hemogenyx Pharmaceuticals plc (LSE: HEMO) is pleased to announce that it has
raised £3,000,000 from a small group of institutional investors to support
the acceleration of its clinical development programmes. The fundraising was
completed through a direct subscription for 374,532 new ordinary shares in the
Company at a market bid price at closing of trading on April 27 of £8.01 per
share.

The net proceeds from the fundraising will be used primarily to accelerate the
Phase I clinical trials of the Company's proprietary Chimeric Antigen Receptor
T-cell therapy, HG-CT-1. This therapy is being developed for the treatment of
relapsed/refractory acute myeloid leukaemia ("R/R AML") in adults and is now
also being extended into paediatric patients.

Early Commercialisation Initiative

In September 2025, the Company announced that it had begun exploring the
potential for early commercialisation of HG-CT-1 through the hospital
exemption pathway under Estonia's Medicinal Products Act. The Company is
pleased to report that the necessary hardware and infrastructure for the
manufacturing of HG-CT-1 in Estonia have now been established.

Hemogenyx, in collaboration with its Estonian partner Cellin Technologies OÜ,
intends to commence the technology transfer process required for local
manufacturing of HG-CT-1 imminently.

The successful completion of this fundraising provides the Company with
additional financial resources to advance its clinical programmes and progress
its early commercialisation strategy for HG-CT-1. Further updates will be
provided in due course.

An application is being made to the Main Market of the London Stock Exchange,
and admission of the Placing Shares to trading is expected on or around May 6,
2026 ("Admission"). The Placing Shares will rank pari passu with the
Company's existing Ordinary Shares.

 

Total Voting Rights

For the purpose of the Disclosure Guidance and Transparency Rules, following
Admission the enlarged issued share capital of the Company will comprise
6,799,961 ordinary shares. The Company does not hold any shares in treasury.
The above figure may be used by shareholders as the denominator for the
calculations by which they will determine if they are required to notify their
interest in, or a change to their interest in, the Company, under the
Disclosure Guidance and Transparency Rules.

Dr Vladislav Sandler, CEO & Co-Founder of Hemogenyx Pharmaceuticals,
commented:

"This fundraising marks an important step forward for Hemogenyx as we continue
to advance HG-CT-1 through clinical development and move closer to potential
early commercialisation. We are pleased to have secured the support of
institutional investors who share our vision of bringing innovative,
life-saving therapies to patients with relapsed or refractory acute myeloid
leukaemia, including children.

The establishment of manufacturing infrastructure in Estonia and our planned
technology transfer with Cellin Technologies represent key milestones in our
strategy to accelerate patient access through the hospital exemption pathway.
We believe this dual approach of progressing clinical trials while preparing
for early commercialisation uniquely positions the Company to create value and
address significant unmet medical needs."

 

UK Market Abuse Regulation (UK MAR) Disclosure

Certain information contained in this announcement would have been inside
information for the purposes of Article 7 of Regulation No 596/2014 (as it
forms part of UK domestic law by virtue of the European Union (Withdrawal) Act
2018) until the release of this announcement. The person responsible for
arranging for the release of this announcement on behalf of Hemogenyx
Pharmaceuticals plc is Dr Vladislav Sandler, Chief Executive Officer &
Co-Founder.

 

Enquiries:

 Hemogenyx Pharmaceuticals plc                                   https://hemogenyx.com (https://hemogenyx.com/)
 Dr Vladislav Sandler, Chief Executive Officer & Co-Founder      headquarters@hemogenyx.com (mailto:headquarters@hemogenyx.com)
 Peter Redmond, Director                                         peter.redmond@hemogenyx.com (mailto:peter.redmond@hemogenyx.com)
 SP Angel Corporate Finance LLP                                  Tel: +44 (0)20 3470 0470
 Matthew Johnson, Vadim Alexandre, Adam Cowl
 AlbR Capital Limited                                            Tel: +44 (0)20 7469 0930
 Lucy Williams, Duncan Vasey, Charles Goodfellow

About Hemogenyx Pharmaceuticals plc

Hemogenyx Pharmaceuticals is a publicly traded company (LSE: HEMO)
headquartered in London, with its US operating subsidiaries, Hemogenyx
Pharmaceuticals LLC and Immugenyx LLC, located in New York City .

The Company is a clinical stage biopharmaceutical group developing new
medicines and treatments to treat blood and autoimmune diseases. Hemogenyx
Pharmaceuticals is developing several distinct and complementary product
candidates, as well as platform technologies that it uses as engines for novel
product development.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOESEUFUWEMSELL



            Copyright 2019 Regulatory News Service, all rights reserved